PR NewswireVANCOUVER, BC, Feb. 27, 2025
USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 27, 2025 /PRNewswire/ -- US
SELLAS Life Sciences (SLS) stock falls following interim results from a Phase 3 REGAL trial for its lead asset, galinpepimut-S (GPS) in blood cancer. Read more here.
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. ( SLS) (”SELLAS” or the ”Company”), a late-stage clinical biopharmaceutic
- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venet
July 19, 2024 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today's roundup of stocks to watch i...
June 18, 2024 (Investorideas.com Newswire) Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases the second of a...
Loading... Loading...
Shares of Ovid Therapeutics Inc OVID dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoin...
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates.
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<
Infrared Cameras Holdings Inc (MSAI) is up over 137% at $6.23. The following are some of the other stocks making big moves in Thursday's pre-market trading..